[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 455
Citations 0
Correction
April 25, 2012

Error in Financial Disclosure in: Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial

JAMA. 2012;307(16):1694. doi:10.1001/jama.2012.536

Error in Financial Disclosure. In the Original Contribution entitled “Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial,” published in the September 21, 2011, issue of JAMA (2011;306[11]:1224-1232), the financial disclosure for Dr March was incorrect. It should have read: “Dr March reported that he is a scientific advisor for Pfizer, Lilly, Bristol-Myers-Squib, and Shire Pharmaceuticals; receives research support from Pfizer, is a member of the data safety and monitoring boards for Otsuka and Lilly, is an equity holder in MedAvante; and receives royalties from MultiSystems for the Multidimensional Anxiety Scale for Children and for books from Guilford and from Oxford University Press.”

×